Title: GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY IN PHYSIOLOGICAL PH BUFFERS

Abstract: Modified glucagon peptides are disclosed having improved solubility while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 23, or both to further enhance the solubility of the glucagon agonist analogs.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC: C07K 14/605(2006.01);A61K 35/37(2006.01),35/38(2006.01)

USPC: 514/12;530/308
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
U.S.: 514/12; 530/308

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:

**“A”** document defining the general state of the art which is not considered to be of particular relevance

**“E”** earlier application or patent published on or after the international filing date

**“L”** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

**“O”** document referring to an oral disclosure, use, exhibition or other means

**“P”** document published prior to the international filing date but later than the priority date claimed

**“T”** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**“X”** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

**“Y”** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

**“&”** document member of the same patent family

Date of the actual completion of the international search: 01 September 2008 (01.09.2008)

Date of mailing of the international search report: 23-SEP-2008

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (571) 273-3201

Authorized officer: Christine J. Szcak
Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet) (April 2007)
Continuation of B. FIELDS SEARCHED Item 3:
WEST: US Patents, US Pre-Grant Publications, Derwent World Patents Index, MEDLINE, EMBASE, BIOSIS
Search terms: glucagon, variants, analogs, position 28, position 29, C-terminus, acidic amino acid